HIF1A and candidiasis: Promoting HIF‐1α stabilisation with the hydroxylase inhibitor CoCl2 promoted fungal death in vitro (human macrophages) and in vivo (mouse) indicating a therapeutic potential for HIF‐1α manipulation in candida infection [55].